Intraocular tumors reside in an immune-privileged site, yet in certain circumstances, they can undergo immune rejection. Ocular tumor rejection can follow one of two pathways. One pathway is CD4 ϩ T cell-dependent and culminates in ischemic necrosis of the tumor and phthisis (atrophy) of the eye. A second pathway is also CD4 ϩ T cell-dependent but does not inflict collateral injury to ocular tissues, and the eye is preserved. We isolated two clones of a murine tumor, Ad5E1 that undergo profoundly different forms of immune rejection in the eye. Clone 2.1 tumors undergo an ischemic necrotizing form of rejection that requires IFN-␥, T cells, and ocular macrophages and culminates in destruction of the eye. By contrast, the second clone of Ad5E1, clone 4, undergoes rejection that also requires T cells and ocular macrophages, but leaves the eye in pristine condition (nonphthisical rejection). Here, we demonstrate that nonphthisical tumor rejection of clone 4 tumors is IFN-␥-independent but requires an ocular macrophage population that contains M1 and M2 macrophages. Clone 4 tumor-bearing eyes displayed ten-and 15-fold increases in M2-and M1-associated markers Arg1 and NO2, respectively. This is in sharp contrast to previous results with clone 2.1 tumor rejection, in which M2 markers were undetectable, and the eye was destroyed. These results suggest that the presence of M2 macrophages tempers the immune rejection of intraocular tumors and promotes immune effectors that inflict minimal injury to innocent bystander cells and thereby preserve the integrity and function of the eye. J. Leukoc. Biol. 92: 939 -950; 2012.
Introduction
Ocular immune privilege is necessary for maintaining the visual axis. Immune-mediated inflammation has devastating consequences on normal ocular cells and can lead to blindness. To reduce the risk of immune-mediated injury, the eye invokes several immunosuppressive mechanisms to maintain immune privilege. The AC of the eye is well-endowed with such mechanisms. The reduced expression or absence of MHC class I molecules on the corneal endothelium lessens the likelihood of injury from infiltrating CD8
ϩ CTLs [1] . The AqH contains a number of anti-inflammatory and immunosuppressive factors, such as TGF-␤, ␣-MSH, and VIP, which serve to quench inflammation [2] [3] [4] . Also, antigens introduced into the AC induce an antigen-specific down-regulation of Th1 DTH immune responses and an isotype shift away from the production of complement-fixing antibodies in a phenomenon known as AC-associated immune deviation [4] . Immune privilege supported by these unique mechanisms promotes prolonged and sometimes permanent survival of foreign tissue and tumor allografts that are placed in the eye [5, 6] . There are circumstances when circumvention of ocular immune privilege is desirable; the most notable is in the case of ocular neoplasms. Animal models have shown that certain ocular tumors can induce a robust, systemic immune response that culminates in tumor rejection that follows two mutually divergent patterns [7] . One pattern of rejection occurs by a CD4 ϩ T cell-mediated process that coincides with the development of DTH responses leading to ischemic necrosis and death of the tumor and innocent bystander ocular cells and also culminates in destruction of the eye [7] . The second pattern of T cell-mediated intraocular tumor rejection is characterized by an intratumoral T cell infiltrate, piecemeal necrosis of intraocular tumor cells, preservation of normal ocular cells, and the absence of phthisis [7, 8] . The immunoregulatory process that determines which of these two pathways is invoked has an enormous impact on the fate of the eye and the preservation of vision.
We have used the Ad5E1 tumor to investigate how ocular immune privilege is circumvented. This tumor undergoes spontaneous immune rejection following transplantation into the AC of syngeneic C57BL/6 mice [9] . During the course of these investigations, we observed two distinct patterns of immune rejection of Ad5E1 tumors. One pattern of intraocular Ad5E1 tumor rejection was characterized by ischemic necrosis and extensive damage to normal ocular tissues that culminated in atrophy of the eye-a condition called phthisis. A second pattern of tumor rejection did not inflict injury to innocent bystander cells and left the eye in a pristine condition-a form of tumor resolution that we have termed nonphthisical rejection. To dissect the immunopathological processes that lead to these widely disparate forms of immune rejection, we isolated two tumor cell clones of the original Ad5E1 tumor that consistently underwent phthisical or nonphthisical rejection, respectively. The Ad5E1 tumor clone that culminated in phthisical rejection in C57BL/6 mice was designated as clone 2.1. Rejection of clone 2.1 tumors occurs by a T cell-dependent immune rejection that is IFN-␥-dependent and requires an intact intraocular macrophage response that provokes the release of NO and TNF-␣, inflicting extensive, irreparable damage to the eye [10] . In this report, we describe a second clone of the Ad5E1 tumor, designated clone 4, which undergoes T cell-dependent immune rejection that also requires macrophages but does not require IFN-␥ or NO and does not culminate in blindness. Although macrophages are necessary for the rejection of both Ad5E1 clones, the fate of the eye is vastly different. With this in mind, we focused our efforts on understanding the mechanisms whereby macrophages contribute to a nonphthisical form of rejection and thus, preserve the anatomical integrity of the eye and vision.
Akin to the Th1/Th2 paradigm, macrophages are polarized into two distinct populations; classically (M1) or alternatively (M2) activated macrophages. Macrophages are polarized into a M1 phenotype in response to IFN-␥ or microbial products such as LPS [11] . M1 macrophages vary in morphology depending on their tissue location but are generally able to produce significant amounts of proinflammatory cytokines, such as IL-1␤, IL-15, IL-18, TNF-␣, IL-23, IL-6, and IL-12 [12] . M1 macrophages have the ability to kill intracellular pathogens and tumors by using a variety of mechanisms, including phagosome acidification, production of TNF-␣, synthesis of reactive oxygen intermediates, and release of NO [13, 14] . M1 macrophages also release a variety of proteases that disrupt biochemical pathways and cellular homeostasis to induce damage and apoptotic cell death. These proteases include MMPs, cysteine, serine, and aspartic proteases [15] . The extent of injury proteases induce depends on the presence of antiproteases that are present in tissues to control damage [16] .
M2 macrophages are categorized as activated macrophages that are not classically identified as M1 macrophages and are grouped according to function. However, M2 macrophages play a critical role in mediating type II immune responses and share a common phenotype of IL-12 low , IL-23 low , and IL-10 high expression [12] . In addition, they generally have high levels of mannose and galactose-type receptors and metabolize arginine to ornithnine and polyamine for proliferation. M2 activation occurs through stimulation with IL-4, IL-10, and IL-13 produced by Th2 cells, mast cells, and basophils [17] . M2 macrophages are also protumorigenic by their production of IL-10, TGF-␤, and expression of IDO, which suppresses anti-tumor Th1 cell responses and promotes the induction of Tregs [18] . Unlike M1 macrophages, M2 macrophages do not express iNOS but express high levels of Arg1, which skews the metabolic pathway of NO to the production of proline [14, 19] and reduces M1 macrophage function significantly [17, 18] . In this study, we demonstrate that intraocular Ad5E1 clone 4 tumors are rejected nonphthisically by mechanisms that are not dependent on IFN-␥. Moreover, macrophage-dependent elimination of Ad5E1 clone 4 ocular tumors appears to occur through a protease-mediated mechanism that results in apoptosis of the tumor cells and involves the participation of M1 and M2 macrophage populations. 
MATERIALS AND METHODS

Animals
Tumor cells
Ad5E1 tumor cells were kindly provided by Dr. Rene E. M. Toes (Leiden University Medical Center, The Netherlands). The parental Ad5E1 tumor cell line was generated by the transformation of C57BL/6 mouse embryo cells with a plasmid encoding the human Ad5E1 and propagated as described previously [21] . Ad5E1 tumors undergo immune rejection in the eyes of syngeneic C57BL/6 mice by a T cell-dependent immune process that leaves the eye intact and anatomically unscathed [9] . The parental Ad5E1 tumor expresses a decapeptide that is presented by the H-2D b MHC molecule and serves as a target for cytolysis by syngeneic CTL [21] . Although the parental Ad5E1 tumor cell line is susceptible to cytolysis by CTL, and adoptively transferred CTL can mediate rejection of intraocular Ad5E1 tumors [21, 22] , CD8
ϩ CTLs are not necessary for the rejection of intraocular Ad5E1 tumors, as these tumors resolve in the eyes of CD8 Ϫ/Ϫ mice or anti-CD8 antibody-treated mice but grow progressively in SCID mice [9, 23] . In subsequent studies, we observed that the original Ad5E1 tumor cultures contained subpopulations that underwent a form of T celldependent immune rejection , which destroyed the tumor and the eye (i.e., phthisical rejection). 
Antibody depletion
For CD8-depleted mice, C57BL/6 mice were injected i.p. with 500 g rat anti-mouse CD8 (YTS169.4) on Day Ϫ2 and the day of tumor injection (Day 0) and then twice weekly throughout the course of tumor growth [24] . This anti-CD8 antibody has been used extensively for the in vivo depletion of CD8 ϩ T cells in mice [24] and has been shown to prevent the rejection of the s.c. Ad5E1 tumors and SV40-induced intraocular tumors in syngeneic mice [25, 26] . For IL-17A depletion, C57BL/6 mice were injected i.p. with 500 g rat anti-mouse monoclonal IL-17A on Day Ϫ2 and the day of tumor injection (Day 0) and then twice weekly throughout the course of tumor growth. The anti-IL-17A mAb hybridoma was generated by the University of Texas Southwestern Hybridoma Facility as described previously [27] . This anti-IL-17A mAb and the dosing regimen have been shown to abolish corneal allograft-induced Tregs and to mitigate experimental dry eye disease in mice [28, 29] . mAb were isolated from hybridoma cultures and affinity-purified. Rat IgG was purchased from Sigma-Aldrich (St. Louis, MO, USA). Ad5E1 clones 4 and 2.1 tumor cell suspensions were injected into the AC as described previously [30] . Mice were anesthetized i.p. with 0.66 mg/kg ketamine hydrochloride (Vetalar; Parke-Davis and Co., Detroit, MI, USA). The eye was viewed at low power (ϫ8) under a dissecting microscope, and a sterile, 30-gauge needle was used to puncture the cornea at the corneoscleral junction, parallel and anterior to the iris. A glass micropipette (diameter ϳ80 ) was fitted onto a sterile infant feeding tube (five French; Tyco Healthcare Group, Mansfield, MA, USA) and mounted onto a 0.1-ml Hamilton syringe (Hamilton, Whittier, CA, USA). A Hamilton automatic dispensing apparatus was used to inject 6 l of a monocellular suspension of Ad5E1 clone 4 tumor cells (3ϫ10 5 cells/6 l or 5ϫ10 4 cells/6 l). Eyes were examined three times/week, and the tumor volume was recorded as the percentage of AC occupied with tumor [30] .
Histology
Tumor rejector eyes were removed from euthanized mice, fixed in formalin, embedded in paraffin, and cut into 5 m sections. Eye sections were stained with H&E to examine pathology of the eye.
Flow cytometric analysis
Surface expression of IFN-␥R was assessed by flow cytometry. After washing 3ϫ with HBSS, cells were maintained in HBSS containing 0.3% BSA. Cells (1ϫ10 6 ) were incubated with 1 g/ml purified anti-mouse IFN-␥R-specific antibody (eBioscience, San Diego, CA, USA) for 30 min at 4°C. Cells were washed 3ϫ with HBSS containing 0.3% BSA, resuspended in 0.5 ml PBS, and assessed for fluorescence in a FACScan flow cytometer (BD Biosciences, Palo Alto, CA, USA). The data were analyzed using CellQuest, version 3.1f, software (BD Biosciences).
Liposome-encapsulated dichloromethylene diphosphonate (clodronate)
Multilamellar liposomes were prepared as described earlier [31] . Briefly, 8 mg cholesterol and 86 mg phosphatidylcholine (Sigma-Aldrich) were dissolved in 10 ml chloroform (Sigma-Aldrich) in a round-bottomed flask. After low-vacuum rotary evaporation at 37°C, a thin film was formed on the inner surface of the flask. This film was then dispersed by gentle rotation for 10 min in PBS for the preparation of PBS-LIP. For C12MDP-LIP, 2.5 g clodronate (Roche, Mannheim, Germany) was dissolved in 10 ml PBS. The suspension was kept for 2 h at room temperature and sonicated for 3 min at 20°C. To remove free C12MDP, the liposomes were washed twice by centrifugation in PBS at 100,000 g for 30 min and resuspended in 4 ml PBS that contained ϳ20 mg C12MDP. Each 100 l C12MDP-LIP suspension contained 1 mg C12MDP. The cytotoxicity of C12MDP-LIP and PBS-LIP was tested using an in vitro toxicity assay using RAW 264.7 macrophages as target cells. C12MDP-LIP (100 l) typically induced 85-90% cytotoxicity of 1 ϫ 10 5 RAW 264.7 cells within 24 h. Liposomes were used immediately, and excess liposomes were stored at 4°C for up to 1 month, after which, the liposomes were discarded.
Macrophage depletion
Previous studies have shown that SCJ injection of C12MDP-LIP (Sigma-Aldrich) induces the elimination of Ͼ95% of the conjunctival macrophages [32] and Ͼ99% depletion of F4/80 ϩ macrophages that infiltrate intraocular Ad5E1 tumors [33] . Multilamellar liposomes were prepared as described above [31] . Under an operating microscope, the conjunctiva was lifted, and the C12MDP-LIP suspension (8 l) was injected into the bulbar conjunctiva using a 30-gauge needle, mounted on a 1-ml tuberculin syringe. Injection of the C12MDP-LIP suspension resulted in a bleb around the injection site. To obtain a more equal distribution of the suspension around the limbus, the dose was divided by injecting at four different sites, 90°apart, around the limbus until a circular conjunctival bleb was obtained. PBS-LIP was used as a negative control for macrophage depletion. Liposome injections were performed on the day of tumor injection and repeated every 3-4 days throughout tumor observation [34] .
Real-time qPCR
Expression of NOS2 and Arg1 mRNA was assessed by real-time qPCR by the MyiQ single-color real-time PCR detection system (Bio-Rad, Hercules, CA, USA). Briefly, 1 g total RNA was converted into first-strand cDNA using the RT 2 first strand kit (SA Biosciences, Frederick, MD, USA), according to the manufacturer's conditions. The PCR amplification reactions contained 1.0 l first-strand cDNA mixed with 12.5 l RT 2 qPCR master mix (SA Biosciences), 10.5 l ddH 2 O, and RT 2 qPCR primers (SA Biosciences) in a final reaction volume of 25 l. All reactions were normalized to GAPDH and performed in duplicate. The PCR profile consisted of an initial denaturation of 10 min at 95°C, 40 cycles of 15 s at 95°C denaturing, and 60 s at 60°C annealing. A dissociation (melting) curve was performed to insure proper quality control for each sample. As a control, RAW 264.7 macrophage cells were polarized to an M1 or M2 phenotype by culturing with IFN-␥ (10 U/ml)/LPS (10 ng/ml) or IL-4/IL-10/IL-13 (each 10 ng/ ml), respectively, for 24 h prior to RNA isolation [10] .
Isolation of BMDMs
BMDMs were isolated as described previously [35] . BM cells were obtained from the femurs of C57BL/6 mice and were cultured with rmM-CSF (10 ng/ml; R&D Systems, Minneapolis, MN, USA) for 7 days.
BMDM-mediated cytotoxicity assay
BMDMs were used to determine the role and possible mechanisms of macrophage-mediated killing of clone 4 tumor cells in vitro as described previously [36] . Briefly, BMDMs were plated 1 ϫ 10 5 /well in 96-well flat-bottom plates and incubated with medium alone or medium containing rmIFN-␥ (10 U/ml; R&D Systems) plus LPS (10 ng/ml; R&D Systems) for 24 h. Ad5E1 clone 4 tumor cells (target cells) were incubated with 0.2 Ci/ml 
Transwell assays
We used transwell assays to investigate whether macrophage-mediated cytotoxicity was contact-dependent. were seeded in the upper chamber. Cells were incubated for 48 h, and the percent of cytotoxicity of tumor cells was determined as detailed above.
Collection of supernatants from macrophage-tumor cell cultures
Supernatants were collected from activated macrophage (5ϫ10 
Detection of apoptotic cells
Labeling with annexin V and PI was processed using the TACS annexin V-FITC apoptosis detection kit (Trevigen, Gaithersburg, MD, USA) and 10 g/ml PI, according to the manufacturer's instructions. A total of 10 5 control or treated cells was processed, and 10 4 cells were analyzed using a FACScan flow cytometer (BD Biosciences) with an excitation wavelength of 488 nm and emission wavelength of 530 nm (for annexin V-FITC) or 585 nm (for PI). The results were analyzed using CellQuest, version 3.1f, software (BD Biosciences).
Protease inhibitors
To identify the class of protease inhibitors involved in macrophage-mediated cytotoxicity, a protease inhibitor set containing 10 protease inhibitors was used (Roche). This protease inhibitor kit was designed by the manufacturer for determination of specific classes of proteases found in tissue-culture media, and the specificity was verified by the manufacturer. Protease inhibitors were prepared according to the manufacturer's instructions. Inhibitors were prepared at a 200ϫ concentration, and 1 l was added to cultures containing
Inhibition of iNOS with L-NAME
L-NAME (Cayman Chemical, Ann Arbor, MI, USA) was used to block iNOS in the in vitro macrophage-mediated cytotoxicity assays at a final concentration of 1 mM and 5 mM [37, 38] . As a control, the biologically inactive isomer, N -nitro-d-arginine methyl ester hydrochloride (Sigma-Aldrich), was used at the same concentrations as L-NAME.
Statistics
Results are expressed as mean Ϯ sem. Differences between experimental and control groups were analyzed by Student's t test. Differences were considered significant if the P values were Ͻ 0.05.
RESULTS
T cells are required for nonphthisical rejection of Ad5E1 clone 4 tumors
Ad5E1 clone 4 tumors consistently underwent nonphthisical rejection following transplantation into the AC of WT C57BL/6 mice and left the architecture of the eye completely intact and indistinguishable from a normal C57BL/6 mouse eye (Figs. 1A and B) . This was in sharp contrast to the rejection of intraocular clone 2.1 tumors that culminated in phthisis (Fig. 1C) . Ad5E1 clone 4 tumors were rejected in C57BL/6 mice beginning around Day 14 and were rejected completely by Day 23 (Fig. 1D) .
To determine whether Ad5E1 clone 4 ocular tumor rejection was immune-mediated, Ad5E1 clone 4 tumor cells were transplanted into the eyes of T and B cell-deficient SCID mice. The inability of immune-deficient SCID mice to reject intraocular Ad5E1 clone 4 tumors demonstrates that rejection was an immune-mediated process that required T cells and possibly B cells (Fig. 1C) .
Nonphthisical rejection of Ad5E1 clone 4 tumors can be mediated by CD4
؉ or CD8 ؉ T cells
As rejection of Ad5E1 clone 4 intraocular tumors was T celldependent, we sought to determine the phenotype of the T cells responsible for tumor resolution. To test the hypothesis that rejection requires CD8 ϩ T cells, C57BL/6 mice were depleted of CD8 ϩ T cells with anti-CD8 antibody prior to AC injection of the tumor cells. Similarly, to test the requirement of CD4 ϩ T cells for rejection, Ad5E1 clone 4 tumor cells were injected into the AC of CD4 KO C57BL/6 mice. Rejection of Ad5E1 clone 4 ocular tumors could be mediated by CD8 ϩ or CD4 ϩ T cells, as AC tumors were rejected nonphthisically in CD8-depleted and in CD4 KO mice ( Fig. 2A and B) . However, Ad5E1 clone 4 ocular tumors grew progressively in CD4 KO mice that were also depleted of CD8 ϩ T cells (data not shown), demonstrating that T cells of either phenotype are sufficient for rejection.
Nonphthisical rejection of Ad5E1 clone 4 does not require IFN-␥
We have shown previously that rejection of intraocular Ad5E1 clone 2.1 tumors was IFN-␥-dependent [25] . To determine whether IFN-␥ was required for rejection of intraocular Ad5E1 clone 4 tumors, IFN-␥ KO mice were injected in the AC with 
Mechanisms that do not promote Ad5E1 clone 4 tumor rejection
The next series of experiments was performed to determine which T cell subpopulations and which factors expressed or elaborated by T cells were required for the rejection of Ad5E1 clone 4 ocular tumors. Accordingly, we tested whether ␥␦ T cells, NKT cells, TRAIL, IL-17, or FasL were necessary for Ad5E1 clone 4 ocular tumor rejection. This was addressed by AC injection of Ad5E1 clone 4 tumor cells into ␥␦ T cell KO, NKT cell KO, TRAIL KO, or FasL-defective mice. Interestingly, Ad5E1 clone 4 intraocular tumors were rejected nonphthisically in all KO mice described above, suggesting that none of these T cell populations or molecules was required for rejection of Ad5E1 clone 4 ocular tumors ( Table 1) .
Nonphthisical intraocular Ad5E1 clone 4 tumor rejection requires macrophages
A substantial amount of evidence suggests that macrophages promote tumor progression. However, there is also ample evidence that macrophages also play an important role in tumor rejection [39] . Previous studies have reported that rejection of parental Ad5E1 intraocular tumors required macrophages [33, 34] ; however, the role of macrophages in phthisical and nonphthisical intraocular tumor rejection has not been examined directly. To determine whether macrophages were required for nonphthisical rejection of Ad5E1 clone 4 ocular tumors, macrophages were depleted locally by SCJ injections of C12MDP-LIP prior to AC tumor injection. C57BL/6 mice were injected in the AC with 3 ϫ 10 5 Ad5E1 clone 4 tumor cells. Following tumor injection, two groups of mice were injected SCJ with clodronate-containing or PBS-LIP, respectively. Liposome injections were repeated every 3-4 days. Depletion of macrophages allowed progressive intraocular tumor growth (Fig. 4A) . By contrast, nonphthisical tumor rejection proceeded unabatedly in mice treated with PBS-LIP and untreated C57BL/6 mice (Fig. 4A ).
Ad5E1 clone 4 tumors cells are susceptible to macrophage-mediated killing
Other investigators have reported that M1 macrophages kill tumor cells directly using in vitro assays [36] . As such, we used in vitro cytotoxicity assays to test whether Ad5E1 clone 4 tumor cells were susceptible to direct macrophage-mediated killing. BMDMs were activated with IFN-␥ and LPS or left without treatment and cocultured with 3 H-thymidine-labeled Ad5E1 clone 4 tumor cells or control B16F10 melanoma tumor cells at an E:T ratio of 10:1 for 48 or 72 h. Activated BMDMs killed Ad5E1 clone 4 tumor cells (75-80%) at 48 and 72 h timepoints (Fig. 4B , and data not shown, respectively), indicating that Ad5E1 clone 4 tumor cells are highly susceptible to macrophage-mediated killing. The susceptibility of B16F10 tumor cells to macrophage-mediated killing was used as a positive control. Unlike Ad5E1 clone 2.1 tumors, macrophage-mediated killing of clone 4 tumor cells was iNOS-independent and was not inhibited by L-NAME (data not shown).
Macrophage-mediated killing is partially contactdependent
We investigated whether macrophages killed clone 4 tumor cells in a contact-dependent manner by using transwells to separate the tumor cells and macrophages using in vitro macrophage-tumor cell cultures.
3 H-Thymidine-labeled Ad5E1 clone 4 tumor cells (1ϫ10 4 ) were plated in the bottom chamber of the transwell apparatus. Activated BMDMs (1ϫ10 5 ) were seeded in the upper chamber. Cells were incubated for 48 h and harvested, and the percent cytotoxicity of tumor cells was determined as detailed above. Separation of the macrophages and Ad5E1 clone 4 tumor cells by a semipermeable membrane (transwell) reduced cytotoxicity of Ad5E1 clone 4 tumor cells from 83% to 52% (Fig. 5) . These results suggest that macrophage-mediated cytotoxicity against Ad5E1 clone 4 tumor cells uses two mechanisms; one that is contact-independent and another one that is contact-dependent.
Macrophages residing in Ad5E1 clone 4 ocular tumors include classically activated (M1) and alternatively activated (M2) macrophage populations
It has been reported that classically activated (M1) macrophages are able to kill tumor cells [12] . The observation that Ad5E1 clone 4 tumor rejection requires macrophages led us to hypothesize that the predominant population of macrophages involved in the rejection of Ad5E1 clone 4 tumors expressed the M1 macrophage phenotype. Ad5E1 clone 4 tumor cells were injected into the AC of WT C57BL/6 mice, and the tumor-bearing eyes were collected on Day 14 (i.e., the peak time of intraocular tumor growth) and homogenized. RNA was isolated immediately, and qPCR was performed to determine the expression of NOS2 (M1 marker) and Arg1 (M2 marker). The expression of two macrophage markers, F4/80 and CD11b, was determined by qPCR to confirm that cells isolated from tumor-bearing eyes included macrophages. As a control, RAW 264.7 macrophage cells were polarized into an M1 or M2 phenotype by culturing with IFN-␥/LPS or IL-4/IL-10/IL-13, respectively. Gene expression levels from all samples were compared with gene expression in cells from naïve eyes and normalized to GAPDH expression. Intraocular Ad5E1 clone 4 tumors expressed increased levels of NOS2 (ϳ14-fold) compared with normal eyes (Fig. 6A) . In addition, Ad5E1 clone 4 tumors expressed increased levels of Arg1 (ϳ11-fold) compared with normal eyes (Fig. 6B) , providing evidence that M1 and M2 macrophages were present in the Ad5E1 clone 4 ocular tumor microenvironment.
Macrophage-mediated killing of Ad5E1 clone 4 tumor cells
As shown above, Ad5E1 clone 4 tumor cells are susceptible to macrophage-mediated killing, in part, through a contact-independent mechanism. To determine if soluble factors mediate rejection, activated macrophages were cultured with Ad5E1 clone 4 tumor cells for 48 h. Supernatants from these cultures were harvested, filter-sterilized to remove cell debris, and added to 3 H-thymdine-labeled Ad5E1 clone 4 tumor cells in culture. Tumor cell cytotoxicity was determined after 48 h of coculture with the supernatant. As with the transwell data, Ad5E1 clone 4 tumors cells were killed effectively by supernatants from AM ϩ T (Fig. 7A) . To ensure that these soluble factors were produced in response to Ad5E1 clone 4 tumor cells, supernatants from activated macrophages cultured alone were added to 3 H-thymidine-labeled Ad5E1 clone 4 tumor cells. This did not affect Ad5E1 clone 4 tumor cell cytotoxicity (data not shown). Similarly, supernatants from intact Ad5E1 clone 4 tumor cells cultured alone did not induce the cytotoxicity of tumor cells (data not shown).
To establish that these soluble factors were proteins, supernatants from AM ϩ T cultures were incubated at 100°C for 10 min, cooled, and added to tumor cells (Fig. 7A) . Heat-inactivated AM ϩ T supernatants were not cytotoxic to Ad5E1 clone 4 tumor cells. Similarly, AM ϩ T supernatants treated with proteinase K were also unable to mediate cytotoxicity, suggesting that the factor or factors in the AM ϩ T supernatant were a protein.
The approximate molecular weight of the protein that mediated Ad5E1 clone 4 tumor cell cytotoxicity was determined by fractionating AM ϩ T supernatants by molecular weight using centrifugal filters with varying pore sizes. Proteins were separated in 3, 10, 30, 50, and 100 kDa fractions. All supernatant fractions were able to mediate tumor cytotoxicity except the 100-kDa fraction (Fig. 7A) . Thus, our data suggest that the soluble factor or factors that mediate cytotoxicity of Ad5E1 clone 4 are a protein or proteins with a molecular weight between 50 and 100 kDa.
To assess the cytotoxicity mediated by the macrophage supernatant-induced tumor cell apoptosis, Ad5E1 clone 4 tumor cells were treated with staurosporine, cultured with AM ϩ T supernatant, or were left untreated. Forty-eight hours later, the tumor cells were stained with annexin V and PI. Flow cytometric analysis demonstrated that Ad5E1 clone 4 tumor cells had an increased percentage of apoptotic cells after treatment with staurosporine (positive control for apoptosis) or AT ϩ M supernatant compared with untreated control Ad5E1 clone 4 tumor cells (Fig. 7B) .
Macrophage cytotoxicity is mediated by multiple macrophage-derived proteases
Experiments examined the possible role of protease activity in mediating Ad5E1 clone 4 tumor cell cytotoxicity. Supernatants from AM ϩ T cell cultures were treated with a broad-spectrum protease inhibitor cocktail. Treatment with this protease inhibitor cocktail completely abolished the cytotoxic effect of supernatants, confirming that the unknown soluble factor was a protease (Fig. 8) . Treatment of tumor cells with the protease in- hibitor cocktail vehicle alone did not induce tumor cytotoxicity (data not shown).
Supernatants were also treated with a panel of protease inhibitors designed to block specific classes of proteases. Protease inhibitors that blocked specific protease classes (e.g., serine proteases or aspartic proteases) were prepared in a vehicle cocktail, according to the manufacturer's instructions, and mixed with AM ϩ T supernatant. Protease inhibitor-treated and untreated AM ϩ T supernatants were added to 3 H-thymdine-labeled Ad5E1 clone 4 tumor cells, and the level of tumor cytotoxicity was determined. Four inhibitors in the panel significantly reduced macrophagemediated cytotoxicity of Ad5E1 clone 4 tumors cells: E-64 (inhibitor of cysteine proteases), Pefabloc® SC (inhibitor of serine proteases), leupeptin (inhibitor of cysteine and serine proteases), and pepstatin (inhibitor of aspartic proteases; Fig. 8 ). Culturing Ad5E1 clone 4 tumor cells with the vehicle cocktail alone did not induce tumor cell killing (data not shown). These results demonstrate that macrophage-induced cytotoxicity appears to be mediated by several different proteases that cleave at multiple amino acid residues.
DISCUSSION
The rejection of intraocular tumors can occur by two divergent patterns that have vastly different histopathological outcomes. Phthisical rejection of intraocular tumors is characterized by damage to the microvascular endothelium surrounding the tumor, ischemic bulk necrosis, and innocent bystander destruction of normal ocular cells [7] . Previous studies using the parental Ad5E1 tumor cell line demonstrated that phthisical tumor rejection is dependent on IFN-␥, NO, and TNF-␣ [10] . In sharp contrast, other tumors can undergo nonphthisical rejection, which is characterized by mononuclear infiltrates comprised of CD4 ϩ T cells, CD8 ϩ T cells, and macrophages, resulting in the piecemeal destruction of tumors without damage to normal ocular cells and little to no ischemia [7, 8] .
In this study, we show that the nonphthisical rejection of Ad5E1 clone 4 tumors can be mediated by CD4 ϩ or CD8 ϩ T cells. However, rejection is not dependent on IFN-␥. Thus, nonphthisical rejection of Ad5E1 clone 4 ocular tumors and phthisical rejection of the Ad5E1 clone 2.1 tumors have a dissimilar requirement for IFN-␥ [10] . Previous studies using the parental Ad5E1 tumor cell line indicated that spontaneous rejection of these intraocular tumors was nonphthisical and required IFN-␥ and CD4 ϩ , but not CD8 ϩ T cells [23, 34] . The previous studies also demonstrated that IFN-␥ acted directly on tumor cells by: inhibiting tumor cell proliferation, inducing tumor cell apoptosis, and simultaneously down-regulating proangiogenic genes and up-regulating antiangiogenic genes in the parental Ad5E1 tumor cells [7, 23, 34, 40, 41] . The role of IFN-␥ in phthisical rejection is related to this cytokine's ability to activate the innate immune system [10] . By contrast, IFN-␥ may act directly on Ad5E1 clone 4 tumor cells by induction of apoptosis and preventing tumor cell proliferation, thereby promoting nonphthisical tumor rejection. Macrophages are crucial for the nonphthisical and phthisical rejection of intraocular Ad5E1 tumors. Like IFN-␥, macrophages may play different roles in nonphthisical rejection and in phthisical rejection. As discussed above, there are two subsets of activated macrophages: M1 macrophages, which are polarized by IFN-␥ and micro-bial products, and M2 macrophages, which are polarized by IL-4, IL-10, and IL-13. M2 macrophages are typically associated with Th2 responses and tend to reduce tissue destruction through the production of immunosuppressive and anti-inflammatory cytokines, such as TGF-␤ and IL-10 [42] .
The function of macrophages in nonphthisical rejection is not clear. As in phthisical rejection of Ad5E1 tumors, nonphthisical rejection of Ad5E1 clone 4 tumors also requires macrophages, as depletion of macrophages leads to progressive growth of intraocular tumors. Here, we demonstrate that cell suspensions from Ad5E1 clone 4 tumor-bearing eyes express the M1 macrophage marker NOS2 and also the M2 macrophage marker Arg1. This suggests that macrophages within intraocular Ad5E1 clone 4 tumors can coexpress markers for M1 and M2 macrophages, or there are two separate populations of macrophages. Unfortunately, we could not isolate sufficient numbers of macrophages from Ad5E1 tumor-bearing eyes to perform functional assays to confirm the presence and activity of distinct M1 and M2 populations. In the absence of such functional data, we can only speculate as to whether the presence of M2 macrophages limits but does not suppress completely the activation and proliferation of M1 macrophages, thereby tempering the release of proinflammatory cytokines and NO. If this does indeed occur in clone 4 tumors, it would explain the absence of innocent bystander injury and phthisis in eyes undergoing tumor rejection.
As mentioned earlier, previous studies of the original Ad5E1 tumor model suggested that nonphthisical rejection relied on macrophages as end-stage effector cells [34] . That is, immune CD4 ϩ T cells collected from mice that had rejected intraocular Ad5E1 tumors were able to adoptively transfer immunity to SCID mice that were subsequently challenged in the AC with Ad5E1 tumor cells. However, depletion of ocular macrophages in SCID mice prior to their receiving immune CD4 ϩ T cells prevented intraocular tumor rejection [34] . Nonetheless, these results do not rule out the possibility that ocular macrophages act to present tumor antigens to infiltrating CD4 ϩ T cells and provide additional stimulation within the intraocular tumors in SCID mice that receive adoptively transferred immune CD4 ϩ T cells. Thus, the role of macrophages in nonphthisical rejection of Ad5E1 clone 4 tumors is probably multifunctional and contributes to the elicitation of the afferent and efferent arms of the immune response. It is noteworthy that Ad5E1 clone 4 tumor cells are highly susceptible to macrophage-mediated killing in vitro. Interestingly, the mechanism macrophages used to eliminate Ad5E1 clone 4 ocular tumors appear to be different from the mechanism macrophages use to eliminate Ad5E1 clone 2.1 ocular tumors. Inhibition of iNOS prevents rejection of Ad5E1 clone 2.1 ocular tumors [10] . By contrast, in vivo inhibition of iNOS does not affect the rejection of Ad5E1 clone 4 tumors and in vitro inhibition of iNOS does not reduce macrophage-mediated cytotoxicity of Ad5E1 clone 4 tumor cells, suggesting that rejection of Ad5E1 clone 4 ocular tumors is not mediated by NO. These findings are consistent with results indicating that clone 2.1 tumorbearing eyes expressed four times as much NOS2 message as clone 4 tumor-bearing eyes [10] . Moreover, clone 4 tumor-bearing eyes displayed a ten-fold increase in the M2 marker Arg1 (Fig. 6) , whereas the expression of Arg1 in clone 2 tumor-bearing eyes was not significantly different from normal, nontumor bearing eyes [10] .
The observation that nonphthisical rejection of intraocular Ad5E1 clone 4 tumors does not produce bystander damage to normal ocular cells also strongly suggests that the NO pathway is not involved in nonphthisical intraocular tumor rejection. Although NO is not required for clone 4 tumor rejection, our data show that intraocular M1 macrophages in tumor-bearing eyes express iNOS, suggesting that NO may be produced and has the potential to damage normal ocular tissues. However, the presence of M2 macrophages, which can cross-regulate M1 macrophages, along with high concentrations of antioxidants in the AqH, may prevent damage to normal tissues. For example, AqH has abundant levels of ascorbic acid, a known antioxidant, which can lead to decreased levels of nitrite in the eye [43] . Also, in contrast to phthisical rejection, TNF-␣ is not required for nonphthisical rejection or for macrophage-mediated killing in vitro. Previous studies using the parental Ad5E1 tumor model indicated that TNF-␣ produced by CD8 ϩ T cells, although not required, was sufficient to mediate nonphthisical tumor rejection [40] . Thus, TNF-␣ may play a similar role in rejection of Ad5E1 clone 4 tumors.
In vitro transwell studies presented here indicated that macrophage-mediated killing occurs through contact-dependent and -independent mechanisms. The macrophage-derived soluble factors that elicit Ad5E1 clone 4 cytotoxicity have a molecular weight between 50 and 100 kDa and are heat-labile. Classically activated macrophages release a variety of proteases that mediate cytotoxicity of tumor cells directly [12] . Here, we demonstrated that the soluble factors released by macrophages in response to tumors cells are proteases, as broad inhibition of protease activity abolished macrophage-tumor culture supernatant cytotoxicity completely when added to Ad5E1 clone 4 tumor cell cultures. The use of protease inhibitors revealed that at least three categories of macrophage-produced proteases mediate cytotoxicity. These proteases classes include cysteine, serine, and aspartic proteases. Proteases, such as MMPs, have been shown to increase invasion and metastasis of many cancer types [44] . Cysteine proteases, such as caspases, promote apoptosis and can function as instigators of cell death [45] . Aspartic proteases, such as cathepsin D, can also promote apoptotic cell death. However, cathepsin D can have a counteracting role, as it has been shown to induce apoptosis in the presence of cytotoxic factors but in other studies, has been shown to have an inhibitory role in apoptosis [46] .
Inhibition of cysteine proteases with cysteine-specific protease inhibitors would decrease macrophage-mediated cytotoxicity of tumor cells. Whether the action of cysteine proteases induces apoptosis directly or indirectly is currently unknown. The inhibition of cysteine proteases may prevent caspase activity, thus limiting apoptosis of tumors cells. Inhibition of serine proteases also reduced macrophage-mediated cytotoxicity. Additionally, macrophages express the serine protease, granzyme B [47] , which can direct the proteolytic activation of executioner procaspases [48, 49] . Thus, it may be possible that macrophage-mediated cytotoxicity involves the production of granzyme B, which promotes Ad5E1 clone 4 tumor cell apoptosis, resulting in nonphthisical rejection in the eye. Although we favor the hypothesis that macrophage-derived proteases mediate tumor cell killing directly, it is possible that macrophagederived proteases induce the production or activation of factors in the tumor cells, which in turn, act as end-stage mediators of tumor cell apoptosis.
We suggest the following model of nonphthisical rejection. DCs, acting as APCs, present Ad5E1 clone 4 tumor antigens to CD4 ϩ T cells and CD8 ϩ T cells. These T cells produce IFN-␥ that polarizes monocytes into M1 macrophages, producing proteases that mediate rejection of the Ad5E1 clone 4 ocular tumors in a nonphthisical pattern of rejection. Ocular macrophages may also be required to present Ad5E1 clone 4 tumor antigens to CD4 ϩ T cells in the eye. Interestingly, Ad5E1 clone 4 tumor-bearing eyes have elevated mRNA expression of M2 macrophage markers, such as Arg1. The role M2 macrophages play in nonphthisical rejection has not been explored. However, it is possible that M2 macrophages may dampen the inflammatory response of M1 macrophages. For instance, M2 macrophages can produce immunosuppressive cytokines, such as IL-10 and TGF-␤ that suppresses the polarization of monocytes to M1 macrophages.
It remains unresolved as to why these two tumor clones, which were derived from the same parental tumor and share antigenic epitopes, provoke profoundly different immunopathological sequelae. Microarray analysis has revealed that the phthisis-inducing clone 2.1 tumor cells display significantly higher expression of the proinflammatory genes HMGB-1, MMP13, and CXCL5 compared with the clone 4 tumor cells that undergo rejection in a nonphthisical pattern (unpublished data). HMGB-1 is secreted by activated macrophages and released by tumor cells during necrotic cell death. Binding of HMGB-1 with its ligand, receptor for advanced glycation end products, induces a local inflammatory response that activates the innate immune system [50] . MMP13 also known as collagenase 3 and is an enzyme that plays a crucial role in ECM degradation and promotes angiogenesis [51] . The chemokine CXCL5 is secreted by activated monocytes and macrophages and promotes inflammation in response to IL-1, IL-17, and TNF-␣ [52] . Interestingly, we have demonstrated previously that although TNF-␣ was not required for rejection of clone 2.1 ocular tumors, it was necessary for the induction of necrotizing inflammation and phthisical rejection [10] . It is possible that TNF-␣ promotes inflammation mediated by CXCL5. Together, expression of these proinflammatory molecules by Ad4E1 clone 2.1 tumor cells may elicit an antitumor response capable of eliminating the tumor that culminates in phthisical tumor rejection.
It is noteworthy that T cells from mice immunized with nonphthisis-inducing Ad5E1 clone 4 tumor cells mediate rejection of clone 4 or clone 2.1 tumors in SCID mouse recipients (unpublished data). However, the immunopathological outcome of the ensuing rejection displays the phenotype of the tumor used in the challenge injection and not the tumor clone used to generate the immune T cells. That is, T cells from mice immunized with clone 4 mediate rejection of clone 2.1 tumors in a manner that culminates in phthisis, whereas immunization with phthisis-inducing clone 2.1 tumor cells induces rejection of clone 4 tumors that leaves the eye in pristine condition. Future studies will focus on identifying the molecular cues elaborated by the respective tumors that prompt the immune system to express nondestructive versus destructive immune effector responses to these two tumors.
The present findings indicate that immune privilege in the AC can be circumvented to rid the eye of a neoplasm without inflicting irreparable injury to innocent bystander tissues and in so doing, preserve vision. Thus, the definition of ocular immune privilege might be revised to include the preservation of immune effector mechanisms that protect the host from infectious agents or neoplasms without jeopardizing the integrity of the eye.
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